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Summary.-The effect of the anabolic steroids nandrolone decanoate and oxymethol-
one on the peripheral blood haemoglobin, total leucocyte and platelet counts was
studied in a controlled trial in which patients received standardized chemotherapy
for one form of malignant disease. The results indicate that these agents have no
protective effect on bone marrow suppression during cytotoxic chemotherapy. It
was observed that the time interval between the initial nadir total leucocyte count
and the return to pre-treatment values in those patients receiving the anabolic
steroids was significantly shorter than in the control group.
IT has long been recognized that adult
males have higher values than females for
red blood cell count, haemoglobin and
haematocrit (Williamson, 1916). This has
been shown to be due to the influence of
androgens on erythropoiesis (Gardner and
Pringle, 1961). Whyte-Watson and Tur-
ner (1959) reported that a greater total
dose of thiotepa could be given to breast
cancer patients before marrow suppression
occurred if they were also treated with
testosterone. Since then, there have been
reports on the use of various androgenic
preparations in conjunction with cytotoxic
agents and radiotherapy, but their value
in this context has not been clearly
established.
A controlled trial has therefore been
carried out to determine the effects of
androgens on various indices of haemato-
poiesis for a limited period of time during
which a group of patients were receiving
a standardized chemotherapeutic regimen
for one form of malignant disease.
PATIENTS AND MIETHODS
The subjects were females with invasive
mole or gestational choriocarcinoma admitted
to Fulham Hospital between December 1968
and March 1971. We excluded from the trial
patients in a " high risk category " who
required intrathecal therapy or additional
cytotoxic drugs from the outset, patients who
had received cytotoxic therapy before ad-
mission, patients who had recently received
multiple transfusions and patients with
evidence of infection. All other patients
were included in the trial.
The androgens used were nandrolone
decanoate (Decadurabolin, Organon) and
oxymetholone (Anapolon, Syntex). After
admission to the trial, randomization of the
subjects was carried out by cards. Initially
there were 2 groups, control and nandrolone
decanoate; later a third group of patients
who received oxymetholone was substituted
for the control group. No attempt was made
to analyse the data until completion of the
trial.
Forty-seven patients etitered the trial
but 6 of these had to be withdrawn. The
reasons for withdrawal were: death during
the period of study (2), development of
intracranial metastases requiring intrathecal
therapy (2), repeated haemorrhage requiring
multiple blood transfusions throughout the
period of study (1), non-standard cytotoxic
therapy (1). The final groups were control-
10 patients, nandrolone decanoate 19
patients, oxymetholone 12 patients. The
groups were matched for patient age, which
ranged from 16 to 37 years.
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received 2 courses of methotrexate given
intravenously, followed by 2 courses given
intramuscularly. The intravenous course
consisted of an initial injection of 7 mg/M2
followed by a constant infusion at a rate of
15 mg/m2/day for 7 days in normal saline.
Folinic acid, 4 mg/M2 was given intra-
muscularly 12 hours after the initial injection
of methotrexate and 12-hourly thereafter
until 12 hours after completion of the
methotrexate infusion. The intramuscular
courses consisted of 50 mg of methotrexate
every 48 hours for 4 doses, with 6 mg of
folinic acid intramuscularly 30 hours after
each injection of methotrexate. There were
7 methotrexate-free days between successive
courses oftreatment.
Nandrolone decanoate was given as a
single intramuscular, " depot " injection of
50 mg/M2 on the first day of methotrexate
therapyandwasnotrepeated. Oxymetholone
was given as a single oral daily dose of100 mg
for 28 days.
All patients had haemoglobin, total
leucocyte and platelet counts performed 3
times weekly. Venous blood samples were
collected into EDTA between 9 a.m. and
11 a.m. with the patients recumbent. The
haemoglobin value was estimated by the
cyanmethaemoglobin method and the packed
cell volume by microhaematocrit. The total
leucocyte and platelet counts were carried
out using a Coulter A counter.
In analysing the data, the period ofstudy
was divided into 4 intervals each corres-
ponding to one course of treatment, i.e.
Days 1-14, 15-28, 29-42 and 43-56. The
results for each group were pooled for these
4 intervals and the means and standard
deviations were calculated for haemoglobin
level, leucocyte count and platelet count.
Pre-treatment values and nadir values for
eachindexweresimilarlypooled andanalysed.
Finally, the total leucocyte and platelet
counts were analysed with respect to the
time interval between the initial nadir and
return to pre-treatment values.
Normal values for the indices analysed
are as shown in Table I (Dacie and Lewis,
1968; Garby, 1970).
RESULTS
The results are summarized in Tables
II, III and IV.
Haemoylobin.-Of the 41 patients for
evaluation, 26 had pre-treatment values
below the normal range quoted. These
anaemic patients were not evenly distri-
buted between the 3 groups (60% of the
controls, 32%ofthenandrolone decanoate,
25% of the oxymetholone were anaemic
treated patients) but the mean differences
in haemoglobin values between the groups
were not statistically significant (P =
> 0.05). Five patients had received
multiple blood transfusions during the
3 months before starting chemotherapy
and 6 patients were transfused up to 3
units of blood during the first week of
treatment.
The trend in the mean haemoglobin
values was upward in all groups despite
treatment, although in several patients an
initial fall occurred. The mean of the
total haemoglobin counts was significantly
higher in both the nandrolone decanoate
and oxymetholone groups compared with
the control group during the first and
second periods (Table III). Nadir values
for haemoglobin showed a similar pattern
of difference during the same periods
(Table IV).
Total leucocyte count.-The pre-treat-
ment leucocyte counts were within the
normal range for all patients in the study
and there was no statistical difference
TABLE II.-Pre-treatment Haematological Values
Haemoglobin g/100 ml
Total white count/mm3
Platelet count/mm3
Control
No. of
counts Mean S.D. (
. 10 11-2 1-6 .
10 6300 1500.
10 192000 52000.
Nandrolone decanoate
No.of
counts Mean S.D. P
19 11-8 1-4 N.S.
19 6600 1600 N.S.
19 218000 56000 N.S.
Oxymetholone
No.of
counts Mean S.D. P
12 12-4 1 9 N.S.
12 6900 2000 N.S.
12 202000 45000 N.S.
S.D. = Standard deviation. P = Level of significance (Student t test). N.S. = Not significant
(P > 0.05).
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TABLE III.-" Total Count" Haematological Values
1st Course
Haemoglobin
g/100 ml
Total white
count/mm3
Platelet
count/mm3
2nd Course
Haemoglobin
g/100 ml
Total white
count/mm3
Platelet
count/mm3
3rd Course
Haemoglobin
g/100 ml
Total white
count/mm3
Platelet
count/mm3
4th Course
Haemoglobin
g/100 ml
Total white
count/mm3
Platelet
count/mm3
Control is
No.of No.c
counts Mean S.D. count
61 10-2 1-4 112
60 4900 1700. 110
60 171000 68000. 105
59 10 - 8 1.1 . 108
59 4700 1500. 107
57 292000 118000 . 105
57 11-5 1.0 111
57 5800 1600 . 110
56 242000 98000. 108
44 11-7 0 9 . 95
44 5700 1500. 95
43 234000 119000 . 93
gandrolone decanoate Oxymetholone
A
Df No. of
ts Mean S.J). P counts Mean S.D. P
11 -2 1 -4 < 0-001.
5400 2100 N.S.
190000 69000 N.S.
11-4 172 <0 005.
4900 1700 N.S.
269000 117000 N.S..
11-8 1.1 N.S.
5800 1600 N.S.
220000 78000 N.S.
11-8 12 N.S.
5700 1400 N.S.
224000 82000 N.S.
71 11-6 1-4 <0.001
71 5100 2100 N.S.
69 162000 59000 N.S.
70 11 6 0-9 <0 001
70 4600 1800 N.S.
70 336000 147000 N.S.
57 11-8 1-0 N.S.
57 6000 2100 N.S.
57 288000 88000 N.S.
49 12-0 0-8 N.S.
49 6100 1600 N.S.
49 243000 60000 N.S.
Key as in Table II.
betweenthe mean pre-treatment values for
the 3 groups. Analysis of the results of
the mean total leucocyte and mean nadir
values showed no significant differences
(Tables III and IV).
The time interval between the initial
nadir leucocyte count and the return
to pre-treatment values was significantly
shorter in both anabolic agent groups than
in the control group (Table V).
Platelet count.-The pre-treatment
platelet counts of the patients all fell
within the normal range and there was no
significant difference between the 3 groups.
No significant difference was observed in
the mean total counts and mean nadir
counts ofthe 3 groups (Tables III and IV),
nor in the rate of return to pre-treatment
values (Table VI).
to
of
DISCUSSION
The objective ofthe present study was
determine whether the administration
anabolic agents for a short period of
time during standardized cytotoxic chem-
otherapy had any significant effect on
peripheral blood countindices. Thelimit-
ing factor in the treatment of malignant
disease with cytotoxic agents is their toxic
effects on normal tissues with a high rate
of cell renewal. The bone marrow is of
particular importance in this respect as
resulting neutropenia and thrombocyto-
penia may predispose to fatal infection or
haemorrhage.
The chemotherapeutic regimen used
produced only mild anaemia and moderate
leucopenia and thrombocytopenia. This
relatively low level of toxicity results
from the intermittent administration of
folinic acid during high dosage metho-
trexate therapy. The same dosage of
methotrexate alone would generally prove
fatal and it is clear that in the treatment
of trophoblastic tumours, the administra-
tion of folinic acid diminishes the effect of
methotrexate on normal tissues with a
high rate of cell renewal, without having a
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TABLE IV.-Nadir Haematological Values
1st Course
Haemoglobin
g/100 ml
Total white
count/mm3
Platelet
count/mm3
2nd Course
Haemoglobin
g/100 ml
Total white
count/mm3
Platelet
count/mm3
3rd Course
Haemoglobin
g/100 ml
Total white
count/mm3
Platelet
count/mm3
4th Course
Haemoglobin
g/100 ml
Total white
count/mm3
Platelet
count/mm3
Control
No. of
counts Mean S.D.
10 9-2 1-3
10 3200 750
10 121000 52000
10 10 0 0 98
10 3100 950
10 192000 66000
10 10.9 0.9
10 4500 1200
10 178000 26000
8 10-9 0-9
8 4300 1300
8 171000 43000.
Nandrolone decanoate
, ~ ~ ~~AA
No.of
counts Mean S.D. P
Oxymetholone
No. of
counts Mean S.D. P
19 10*4 1-3 <0.05 . 12 10 7 1?2 <0-02
19 3800 1000 N.S. . 12 3500 1500 N.S.
19 135000 41000 N.S. 12 118000 32000 N.S.
19 10 - 7 0 96 N.S. . 12 10.8 0.76 N.S.
19 3600 1200 N.S. 12 3000 620 N.S.
19 178000 97000 N.S. . 12 220000 63000 N.S.
19 11*2 1-2 N.S. 10 11-2 0 9 N.S.
19 4500 1100 N.S. . 10 4900 1800 N.S.
19 171000 68000 N.S. . 10 227000 47000 N.S.
17 11.4 1.1 N.S. 8 11 8 0-8 N.S.
17 4400 1100 N.S. . 8 5200 1400 N.S.
17 162000 48000 N.S. 8 194000 48000 N.S.
Key as in Table II.
comparable protective effect on the target
tissue. Any effect from the anabolic
agents would therefore have to be addi-
tional to the sparing action of the folinic
acid.
Nandrolone decanoate and oxymeth-
olone are both synthetic steroids with a
high anabolic and low androgenic activity.
Nandrolone decanoate is also a long
acting preparation. Both have been
shown to have an effect on erythropoiesis
(Turner, 1966; Sanchez-Medal et al., 1964).
Haemoglobin.-Although the group of
patients studied here allowed us to use a
standardized therapeutic regimen and the
results appear to be significant for the
first 2 treatment courses, many other
factors make it difficult to place any
importance on these results. These fac-
tors include: (1) In other studies using
anabolic steroids in the treatment of re-
fractory anaemias, no effect on erythro-
poiesis has been noted until 8 weeks after
commencement of therapy (Kennedy,
1962;; Sanchez-Medal et al., 1969); (2)
higher doses ofanabolic steroids have been
used in these studies (Turner, 1966;
Sanchez-Medal et al., 1969); (3) malignant
disease itself may be accompanied by an
anaemia; (4) changes in plasma volume;
(5) variable amounts of bleeding from
trophoblastic tumours; (6) unequal distri-
bution of pre-treatment haemoglobin
values in the present study; (7) transfu-
sions given to several patients during the
first 7 days of therapy (no patient re-
ceived other haematinic therapy); (8)
variable nutritional status; (9) variable
factors associated with trophoblastic di-
sease and known to have an effect on
erythropoiesis, such as oestrogen and
thyroxine levels (Bagshawe, 1969; Win-
trobe, 1967).
The haemoglobin trend in patients in
all groups was upwards towards normal
values, and this was so even in those with
an initial low haemoglobin level without
transfusion or haematinic therapy and
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TABLE V.-To Compare the Time Interval Between the Nadir Total White Count and
the Return toPre-treatment Count in Association With theFirst Course ofTherapy
Control Nandrolone decanoate Oxymetholone
(a) Number of patients . 10 * 19 12
(b) Mean nadir after commencing 10 * 10 * 9
therapy (days)
(c) Mean return to normal (days) 18 * 15 145-
(d) Mean time interval (b-c) (days) 8 ±2 5 (S.D.) . 5±2*3 (P= <0005) .5*5+2*5(P= <0*025)
TABLE VI.-To Compare the Time Interval Between the Nadir Platelet Count and
the Return to Pre-treatment Count in Association With the First Course of Therapy
Control Nandrolone decanoate Oxymetholone
(a)
(b)
(c)
(d)
Number of patients . 10 . 19
Mean nadir after commencing 12 . 12-5
therapy (days)
Mean return to normal (days) 20 . 21
Mean time interval (b-+c) (days) 8±1* (S.D.) 8 5± I *3 (P =N.S.)
despite cytotoxic therapy. This may be
explained by replacement of red cell mass
after previous haemorrhage, by improved
nutritional status and by successful treat-
ment of the tumour.
It is probably not unreasonable, de-
spite the above, to conclude that the cyto-
toxic therapy was at least a contributing
factor in the initial fall in haemoglobin
values observed in some patients; whether
the anabolic steroids played any part in
its correction is uncertain.
Leucocyte count. Although no detailed
analysis of differential leucocyte counts
was made in this study, the overall im-
pression was that the fall intotal leucocyte
count was due to a fall in neutrophil
count, the lymphocyte count remaining
relatively constant. This has previously
been demonstrated (Shaw, 1971). The
beneficial effect of nandrolone phenyl-
propionate on the lymphocyte count in
rats treated with chlorambucil has been
demonstrated by Johnston and Burn
(1966).
The evidence of a normal neutrophil
cycle suggests the presence of factors
controlling leucocyte production and the
rate of their release into the circulation
(Morley, 1966). These have been sup-
ported by Gordon (1960) in animal
experiments. Small doses of cytotoxic
drugs exaggerate this naturally occurring
neutrophil cycle and cell counts taken at
12
12
20
8±1-6(P=N.S.)
random may thus be taken either at the
peak or trough of a cycle. Increasing the
dosage and duration of cytotoxic drugs
causes a marked decrease in production
ofneutrophils and a sustained non-cyclical
neutropenia (Morley and Stohlman,
1970; King-Smith and Morley, 1970).
During the first course of cyclical metho-
trexate-folinic acid therapy, a nadir
leucocyte count was reached on Day 10
of treatment and this was followed by a
rise to pre-treatment values with no
overshoot. A similar phenomenon
occurs in association with the second
course of therapy although the nadir
reached is somewhat higher. Following
this, the leucocyte count tends to stabilize
at a below-normal level (Shaw, 1971).
The beneficial effect of anabolic steroids
mightthen be either to minimize the initial
leucocyte nadir or to cause stabilization of
the leucocyte count at a higher value.
Neither of these can be confirmed in the
present study although it is possible that
a longer study period might yield different
results.
The interval between nadir and return
to pre-treatment values in those patients
receiving the anabolic steroids was signi-
ficantly shorter than in the controls. This
has previously been reported by Horn,
Robinson and Hochman (1968) in a study
of patients receiving various cytotoxic
agents, plus or minus radiotherapy,
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together with testosterone. The clinical
importance of this finding remains to be
evaluated.
Platelet count.-In the present study,
no beneficial effect of anabolic steroids on
the platelet count could be shown. The
previously reported initial thrombocyto-
penia followed byrebound thrombocytosis
is confirmed (Berlin et al., 1963).
In conclusion, the present study does
not lend much support for the use of
anabolic steroids in an attempt to mini-
mize marrow toxicity during cytotoxic
chemotherapy. Nevertheless, it is a
limited short-term study on a selected
group ofpatients being treated with cycli-
cal methotrexate-folinic acid. Further
studies will be necessary before a conclu-
sion can be reached, but the difficulties
inherent in finding standardized groups
of patients with malignant disease for
long-term study are numerous. Also,
account has to be taken of the report by
Delamore and Geary (1971) that 4 patients
with aplastic anaemia developed acute
myeloblastic leukaemia after treatment
with oxymetholone.
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